WallStSmart
NXGL

Nexgel Inc

NASDAQ: NXGL · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$0.59
-1.63% today

Updated 2026-04-30

Market cap
$5.14M
P/E ratio
P/S ratio
0.45x
EPS (TTM)
$-0.38
Dividend yield
52W range
$1 – $3
Volume
0.4M

Nexgel Inc (NXGL) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for NXGL.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 28 / 100
P/E (TTM)
Not meaningful for this profile
PEG
Margin of Safety
+76.82%
Fair value $6.04 vs $0.59
EV / EBITDA
0.0x

NXGL historical valuation range

Where current P/E sits in NXGL's own 5Y range.

Insufficient historical data for 5Y percentile analysis

NXGL intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

Current price
$0.59
Market value
Intrinsic value
$6.04
DCF estimate
Margin of safety
+76.82%
+923.4% upside to fair value

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

NXGL valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

Strong margin of safety
Current price 76.8% below DCF intrinsic value estimate. Meaningful downside cushion.
Weak financial quality
Piotroski F-Score of 0/9 suggests deteriorating fundamentals. Valuation requires closer scrutiny.

P/E Ratio — History

No historical P/E data available

P/S Ratio — History

Current: 0.45x

Is NXGL overvalued in 2026?

Nexgel Inc (NXGL) currently trades at $0.59 per share with a market capitalization of $5,144,700.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 28/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

NXGL currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.5x, the market is valuing the company primarily on its revenue rather than its earnings.

Our discounted cash flow model estimates NXGL's intrinsic value at $6.04 per share, against the current market price of $0.59. This implies a margin of safety of +76.82%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.

Financial quality is a concern. The Piotroski F-Score of 0/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.

Bottom line: NXGL appears richly valued on our framework, with a Smart Value Score of 28/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is NXGL overvalued in 2026?

Based on a Smart Value Score of 28/100, NXGL appears overvalued. Current price exceeds what fundamentals currently justify.

What is NXGL's fair value?

Our DCF model estimates NXGL's intrinsic value at $6.04 per share, versus the current price of $0.59. This produces a margin of safety of +76.82%.

What P/E ratio does NXGL trade at?

NXGL does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.

Is NXGL a buy based on valuation?

WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 28/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.

How does NXGL's valuation compare to its history?

Insufficient historical valuation data exists yet for a confident percentile read on NXGL.

What is NXGL's Smart Value Score?

NXGL's Smart Value Score is 28/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.